Zoliflodacin

Summary

Zoliflodacin (CHEMBL3544978) is a phase-3 clinical-stage small molecule; indicated across 1 condition including gonorrhea.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 7
• Chemistry: 487.4 Da · C22H22FN5O7

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3544978
Name	Zoliflodacin
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	76685216
Molecular formula	C22H22FN5O7
Molecular weight	487.4
InChIKey	ZSWMIFNWDQEXDT-ZESJGQACSA-N

SMILES: C[C@@H]1CN2[C@H]([C@@H](O1)C)C3(CC4=CC5=C(C(=C42)F)ON=C5N6[C@H](COC6=O)C)C(=O)NC(=O)NC3=O

IUPAC name: (4’R,6’S,7’S)-17’-fluoro-4’,6’-dimethyl-13’-[(4S)-4-methyl-2-oxo-1,3-oxazolidin-3-yl]spiro[1,3-diazinane-5,8’-5,15-dioxa-2,14-diazatetracyclo[8.7.0.02,7.012,16]heptadeca-1(17),10,12(16),13-tetraene]-2,4,6-trione

Also known as: AZD-0914, AZD0914, ETX-0914, ETX0914, Zoliflodacin, Zoliflodacina, Zoliflodacine, ZOLIFLODACIN, US8889671, 5

Patent coverage: 24 distinct patent families (73 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
	DNA gyrase		6.77

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: DNA gyrase subunit A, DNA gyrase, DNA gyrase subunit A/DNA gyrase subunit B.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 3 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P0AES4	6.77	IC50	169	nM	CHEMBL_ACT_17655962
P0A0K8	5.37	IC50	4300	nM	CHEMBL_ACT_24921768

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
gonorrhea	3	MONDO:0004277	DOID:7551

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
PHASE1	5
PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03959527	PHASE3	COMPLETED	Zoliflodacin in Uncomplicated Gonorrhoea
NCT02257918	PHASE2	COMPLETED	Randomized, Open-label Phase 2 Study of Oral AZD0914 in the Treatment of Gonorrhea
NCT02298920	PHASE1	COMPLETED	AZD0914 Phase 1 ADME Study in Healthy Volunteers
NCT03404167	PHASE1	COMPLETED	A Study to Evaluate the Safety, Tolerability and Plasma PK of a Single Oral Dose of Zoliflodacin in Healthy Male and Female Volunteers
NCT03613649	PHASE1	COMPLETED	Thorough QT/QTC (TQT) Clinical Trial to Evaluate the Effect of Zoliflodacin on Cardiac Repolarization in Healthy Male and Female Subjects
NCT03718806	PHASE1	COMPLETED	Study to Investigate Effect of Food and Safety of a New Formulation of Zoliflodacin
NCT05635305	PHASE1	COMPLETED	Zoliflodacin Bioequivalence and Drug-Drug Interaction Study

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).